List: $34B In Pharma Sales Lose Patent in 2014

The very smart and hard-working Tracy Staton at FiercePharma puts together some of the most useful lists for investors in the healthcare field, and few deserve as close a reading as her recent list of the top drugs facing patent expiration in 2014.

The total amount of industry sales facing patent expiration next year is $34 billion, Staton reports. That’s up from $28 billion during 2013. Bigger expiration years? $55 billion in 2012. And watch out for 2015: $66 billion.

Equity research tools can help better understand each company's situation. Here is the top five for 2014, with charts to provide context on the affected companies, according to Staton and FiercePharma:

Teva’s (TEVA) Copaxone, with global 2012 sales of $4 billion, loses protection in May 2014. It’s a multiple sclerosis treatment.

TEVA Revenue (TTM) Chart

TEVA Revenue (TTM) data by YCharts

AstraZeneca’s (AZN) Nexium, global sales of about $4 billion, loses patent protection in May 2014. Nexium treats heartburn and reflux.

AZN Revenue (TTM) Chart

AZN Revenue (TTM) data by YCharts

Boehringer Ingelheim’s Micardis, global sales of about $2.2 billion, goes off patent in January 2014. Micardis treats hypertension. Boehringer is privately-held.

Novartis (NVS) is losing patent protection on two big drugs. Its Sandostatin LAR, global sales $1.5 billion, goes off patent in June 2014. It treats cancer. And its Exforge, global sales about $1.4 billion, goes off patent in October 2014.

NVS Revenue (TTM) Chart

NVS Revenue (TTM) data by YCharts

(These patent expiration dates are generally U.S. dates. Expirations in other countries occur at different dates, frequently. And the percentage of global sales that occur in the U.S. among these drugs varies widely, as you can see by reading the full FiercePharma report.)

Rounding out the top ten expiring patents for 2014 are drugs sold by Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Sanofi (SNY) and Allergan (AGN).

Jeff Bailey, The Editor of YCharts, is a former reporter, editor and columnist at the Wall Street Journal and New York Times. He can be reached at Read the RIABiz profile of YCharts. You can also request a demonstration of YCharts Platinum.



Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{}} No credit card required.

Already a subscriber? Sign in.